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1. Introduction  
Type 1 (T1DM) proceeds from a complete absence of insulin due to an autoimmune-
associated degradation of the insulin-secreting pancreatic ǃ-cell. An islet autoimmune 
response seems to be regulated by the T-helper lymphocyte and its cytokine products 
including IL-2, IFN-Ǆ, and TNF-ǃ, causing a cascade of inflammatory processes, known as 
insulitis and consequently gradual ǃ-cell degradation (Rabinovitch and Suarez-Pinzon 
2003). Therefore, T1DM etiology follows two stages. First, insulitis appears when various 
leukocytes attack the pancreas islets. Second, diabetes develops when most ǃ-cells have 
been degraded, and there is no longer adequate insulin secretion to regulate blood glucose 
levels, leading to hyperglycemia (Mathis, Vence et al. 2001). Chronic hyperglycemia is 
believed to cause insulin resistance in T1DM (Patti, Maffettone et al. 1999). Thus, people can 
have concealed insulitis for years before it finally induces overt diabetes. Although most of 
diabetic patients suffer from T2DM, compelling evidence demonstrated that a proportion of 
people initially diagnosed with T2DM may in fact have a gradually progressing and less 
severe category of T1DM (Bell and Polonsky 2001). People affected by T1DM are 
constrained to insulin administration on a regular basis either through injections, pumps, or 
by inhalation. Outwardly, T1DM patients appear predominantly healthy; however failure to 
adhere to the appropriate treatment to effectively control blood glucose levels could lead to 
increased fatigue, neuropathies and long-term organ damages. The consequences of the 
autoimmunological destruction of pancreatic ǃ-cells are clear, the causes are not, and the 
identification of the environmental factors that induce this destruction in genetically 
susceptible children, adolescents, and even adults still eludes us (Mathis, Vence et al. 2001). 
2. Inflammation 
In T1DM, it is suggested that inflammation contributes to the inhibition or stimulation of ǃ-
cell reformation and ǃ-cell destruction, leading to peripheral insulin resistance (Eizirik, Colli 
et al. 2009). Inflammation is brought on by various cell mediators or cellular signals. Among 
them, cytokines, such as members of the interleukin family (IL-6, IL-1), tumor necrosis 
super family (TNF-ǂ), and the interferon family (INF-, , and Ǆ), play an essential role in 
initiating and perpetuating the inflammatory process. Most of the T1DM-associated 
cytokines are involved in inflammation induced cellular apoptosis through the activation of 
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a specific transcription factor: nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-B).  
2.1 Immunity and T1DM 
In order to better understand the etiology of T1DM, plethora of research has been done to 
link the systematic destruction of ǃ- cells and immunity. In all mammals there are two types 
of immune responses: adaptive and innate those mainly differ with regards to the types of 
receptors that recognize antigens. Innate responses are non-specific compare to adaptive 
which are fairly specialized based on the antigen. The key cellular players of innate 
immunity are dendritic cells, macrophages, mast cells and natural killer cells. They function 
through complex systems of T-cell surface receptors that recognize and destroy antigens 
produced from micro-organisms. Adaptive immunity is more specific, employing T and B 
cells that provide life-long immunity following the immunization process. 
2.1.1 The role of innate immunity in T1DM 
Activation of the receptors involved in innate immunity contributes to the development of 
autoimmune diseases including insulitis and T1DM. Pattern-recognition receptors (PRRs) 
are a class of receptors involved in the innate immune response and includes toll-like 
receptors (TLRs). It is possible that the binding of endogenous ligands to PRRs, specifically 
TLRs, may induce the inflammatory response that leads to ǃ-cell destruction and T1DM. 
This theory is supported by animal models of autoimmune dysfunction; whereby TLRs 
contributed to an innate immune response to pancreatic ǃ-cells and led to insulitis and 
T1DM (Zipris 2008). Specifically, TLR2 and TLR4 deficient mice were resistant to post-
transplantation of islet cells induced T1DM and related inflammation (Goldberg, Parolini et 
al. 2007; Kim, Han et al. 2007). Although experiments such as these support a link between 
specific PRRs and T1DM development, other data suggest complex interactions between the 
immune system, genes, and other biochemical factors. For example, there was no difference 
in T1DM prevalence observed when TLR2 and TLR4 were genetically deleted from non-
obese diabetic mice (NOD) (Wen, Ley et al. 2008). In that study, the nature of the animal’s 
intestinal flora was thought to counter the effect of TLRs’ absence. Other studies support 
that ǃ-cell death can be caused by viral infections, most notably from enteroviruses, as viral 
antigens can elicit an acute inflammatory response. Enteroviruses infection occurred in half 
the subjects in a study assessing ǃ-cells in patients with T1DM (Dotta, Censini et al. 2007). In 
addition, T1DM is characterized as an autoimmune disorder, as ǃ-cells are also accessible to 
antigens-presenting cells: macrophages and dendritic cells. Therefore, macrophages are 
recruited to the pancreas of people suffering from T1DM and insulitis where they produce 
inflammatory cytokines such as IL-1ǃ and TNF-, involved in ǃ-cell death (Uno, Imagawa et 
al. 2007). It has been also suggested that patients with T1DM have alterations in innate 
immunity in the peripheral blood, specifically in dendritic cells, mononuclear and 
plasmacytoid . These data support links between -cell death, inflammation and innate 
immune responses and provide evidence that the innate immunity is a target of choice for 
T1DM treatments. 
2.1.2 The role of adaptive immunity in T1DM 
The nature of the biochemical reactions that occur during and following an acute 
inflammatory response may be key to determining whether autoimmunity develops with 
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the potential to destroy ǃ-cells and progress to T1DM. Altered expression of chemokines, 
signaling molecules that direct immune cells during inflammation, has been observed in 
several autoimmune disorders including T1DM. Certain chemokines such as CCL3, CCL4, 
CXCL10, have been shown to be elevated in T1DM patients (Shimada, Morimoto et al. 2001; 
Nicoletti, Conget et al. 2002; Hanifi-Moghaddam, Kappler et al. 2006). CCL3 has also been 
negatively correlated with C-peptide which is involved in insulin action (Pfleger, Kaas et al. 
2008). Due to the difficulty accessing the pancreatic tissues to observe inflammatory 
markers, new methods have been developed to measure the response of immune cells from 
the systemic circulation in patients with T1DM. Using genetic microarray analysis, a T1DM 
“signature” pattern of chemokine and cytokine expression was revealed (Wang, Jia et al. 
2008). Animal models of T1DM have displayed macrophages islet infiltration during the 
initial stages of the disease, responsible for chemokines production, namely CXCL10 and 
CCL2 (Martin, Rankin et al. 2008). Indeed, high levels of CCL2 in human islets have been 
associated with poor treatment prognosis after islet transplantation (Piemonti, Leone et al. 
2002). Other chemokines have also been implicated in the development of autoimmune 
diabetes including CCL3 and CCL5 both of which have been positively correlated with 
insulitis and islet destruction in a murine model (Abdi, Smith et al. 2002). When exposed to 
inflammatory mediators during insulitis, it has been shown that the ǃ-cells themselves can 
produce cytokines and chemokines (Eizirik, Moore et al. 2008). The expression of 
chemokines by ǃ-cells is at mainly regulated by NF-B, which also mediates ǃ-cell death 
(Eldor, Yeffet et al. 2006). It is believed that dying ǃ-cells may fuel the initial development of 
the autoimmune response which characterizes T1DM (Eizirik and Mandrup-Poulsen 2001; 
Cnop, Welsh et al. 2005). Proteins production resulting from an acute bout of islet 
inflammation, such as cytokines and chemokines, may facilitate the presentation of 
apoptosed ǃ-cells to lymphocytes involved in the adaptive immune response (Filippi and 
von Herrath 2005). Another interesting mechanism by which ǃ-cells fall victim to the 
adaptive immune system is through a stress response initiated by an accumulation of 
misfolded proteins in the ǃ-cell endoplasmic reticulum (ER) (Cardozo, Ortis et al. 2005; 
Dogusan, Garcia et al. 2008). The presence of such proteins occurs as a result of inflammation 
in and around ǃ-cells. Normally, the stress response to misfolded proteins restores balance to 
the ER by shuttling proteins out and preventing synthesis of new proteins into the ER. 
However, an error in this system can result in increased ER stress and ǃ-cell apoptosis 
initiating the adaptive immune response (Cardozo, Ortis et al. 2005). Given the fact that insulin 
accounts for roughly half of the proteins produced by ǃ-cells, therefore it is likely that the 
accumulation of misfolded insulin-related proteins could contribute to ER stress and the 
resulting response. As part of the dying ǃ-cells, insulin could become a antigen recognized by 
effectors cells, thus explaining the autoimmune origin to ǃ-cells apoptosis that occurs in 
T1DM. Ironically, the same inflammatory mediators involved in ǃ-cell destruction may also 
contribute to ǃ-cell proliferation and thus, the resolution of insulitis (Sarvetnick and Gu 1992; 
Sherry, Kushner et al. 2006). Although not yet observed in humans, ǃ-cell proliferation has 
been seen in mice genetically modified to express high cytokine levels, and 
immunosuppression has also been shown to suppress ǃ-cell generation (32). 
2.1.2 At the frontier of inflammation and apoptosis: NF-B signalling in T1DM 
NF-B, known as the “master regulator” of the inflammatory process, is a multi-protein 
complex transcription factor that mediates more than 200 genes. There are several internal 
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and external factors associated with T1DM that affect the activation of NF-B, most notably: 
reactive oxygen species (ROS), TNF-ǂ, IL-1ǃ, nitric oxide (NO) and inducible nitric oxide 
synthase (iNOS). Proper regulation of NF-B is crucial for a healthy immune response. 
Conversely, a disruption in the NF-B pathway often leads to the onset and/or progression 
of several types of cancers as well as viral infections, impaired immune function, and 
autoimmune disorders. It has been suggested that the ability to regulate specific cytokines, 
proteins or genes that activate the NF-B cascade is crucial at slowing the progression of 
T1DM. For example, inflammation triggers NO production, an important transcription 
factor in iNOS gene expression, which then activates NF-B in peripheral blood 
mononuclear cells (Igoillo-Esteve, Gurzov et al.). A recent study demonstrated an up-
regulation of the expression of B-cell lymphoma-6 (Bcl-6), a sequence-specific repressor of 
transcription, in ǃ-cells which decreased programmed cell death, iNOS expression, NO 
production, and NF-B activation (Igoillo-Esteve, Gurzov et al.). This reveals the essential 
role that NF-B signaling can play in ǃ-cell damage and/or destruction. This notion has 
been demonstrated using transgenic mouse models where genes associated with NF-B 
activation have been over expressed or knocked-down (Mathews, Suarez-Pinzon et al. 2005). 
ALR/Lt transgenic mice, which ǃ-cells are engineered to resist apoptosis, showed resistance 
to stress induced by free radical damage. This resistance causes a failure in the production of 
pro-inflammatory cytokines (IL1-ǃ, TNF, and IFN) by inhibiting NF-B activation. These 
outcomes coupled with decreased ROS accumulation leads to decreased ǃ-cell death 
(Mathews, Suarez-Pinzon et al. 2005). More recently, the role of NF-B has been associated 
with chromatin modifying enzymes, histone acetyltransferase, and histone deacetylase 
(HDAC). Positive effects associated with NF-B expression on HDAC inhibition have been 
obtained for several inflammatory diseases (Keslacy, Tliba et al. 2007). HDAC inhibition 
lowered cytokine-mediated insulin resistance and increased iNOS levels, NO formation, and 
apoptosis. IL-1-ǃ induced a biphasic phosphorylation of inhibitor protein IBǂ with the 
second peak in the phase being sensitive to HDAC (Larsen, Tonnesen et al. 2007). These 
studies clearly demonstrate the contribution of NF-B cascade activation to T1DM. 
2.1.3 Transplantation of islet cells only promising because of inflammation? 
Transplanting islet cells is a technique that has emerged in the past few years for treating 
individuals with T1DM. The current therapy is life-long exogenous insulin supplementation 
(Gillespie 2006). Although exogenous insulin administration is generally effective, it does 
not allow for physiological control over blood glucose levels resulting in micro and 
macrovascular consequences. Even when delivered in steady-controlled doses via insulin 
pumps, the results are not as effective as islet transplantation. Islet cells transplantation 
appears as a treatment of choice for T1DM, however, recent five-year follow-up studies 
showed that most of the islet cells that were transplanted were destroyed due to 
inflammation activation (Nanji and Shapiro 2004; Balamurugan, Bottino et al. 2006). Islet 
cells have a unique transplantation progression, as the rejection of the graft does not seem to 
follow the same rejection processes observed during other whole organ transplants. It has 
been shown that instead of the tissue itself, rejection was related to islet quality and 
vascularization, innate immunity, and coagulation (Swift, Clayton et al. 1998; Bach, Bendelac 
et al. 2004). Non-specific inflammation at the site of transplantation can occur in islet ǃ-cells. 
In transplant models, stress as a result of the isolation procedure induced secretion of 
proinflammatory cytokines contributing to early islet graft loss after transplantation. This 
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could represent one of the contributing factors for the destruction of the islet graft over time 
(Barbe-Tuana, Klein et al. 2006). A potential method of ensuring proper graft transplantation 
acceptance could result from CD40. It is a member of the TNF receptor family that binds to 
CD40L and is expressed in pancreatic ǃ-cells. CD40 upregulates intracellular adhesion 
molecule-1 associated with inflammation at both transcriptional and translational levels. 
Inhibition of CD40 expression decreased in a dose dependent manner NF-B-associated 
proinflammatory cytokines and protected human pancreatic duct cells (Vosters, Beuneu et 
al. 2008).  
3. Insulin signaling: between treatment and etiology in T1DM 
Inflammatory mediators from adaptive immune response are likely involved in the 
resolution or maintenance of insulitis that ultimately leading to T1DM. However, despite 
exhibiting the level of hyperglycemia recognized in T1DM diagnosis, some patients 
demonstrate higher insulin levels than would be expected with severe ǃ-cell destruction. It 
has been hypothesized that the inflammatory mediators involved in ǃ-cell dysfunction may 
also contribute to peripheral insulin resistance, thus resulting in the observed 
hyperglycemia (Strandell, Eizirik et al. 1990). Therefore, it is possible that the metabolic 
abnormalities of T1DM are the result of the associated development of progressive insulitis 
and insulin resistance. Though the consequences of progressive insulitis and T1DM can be 
dire, not all individuals who develop insulitis proceed to a full-fledged T1DM diagnosis 
(Eizirik, Sandler et al. 1993).  
3.1 Underlying insulin signaling mechanisms on glucose transport 
Insulin is the primary regulator of blood glucose level and a key signaling to better 
understand the pathology of T1DM. Biologically active human insulin consists of two 
polypeptide chains, the A chain (21 amino acids) and B chain (30 amino acids), joined by 
two interchain disulfide-linked bridges at A-Cys7/B-Cys7 and A-Cys20/B-Cys19 with an 
interconnnected disulfide bridge between A-Cys20/A-Cys11 (Steiner, 1985). Insulin triggers 
a wide variety of metabolic and mitogenic events by activating a series of intracellular 
signaling cascades (Zierath 2002; Wright, Ryals et al. 2004). The effect of insulin is mediated 
through binding to the heterotetrameric insulin receptor (IR) and activating intrinsic 
tyrosine kinase activity via autophosphorylation (Farese 2001). Phosphorylated tyrosine 
residues on the activated IR provide docking sites for insulin receptor substrates (IRSs) that 
contain SH2 (Src-homology 2) domains. IRS-1 and IRS-2 are widely expressed in tissues 
metabolically involved in glucose and lipid homeostasis (Sun, Rothenberg et al. 1991; Sun, 
Wang et al. 1995), and are therefore found in skeletal muscle, liver, fat, and pancreatic islets. 
While IRS-1 appears to play a more important role in skeletal muscle metabolism than IRS-2, 
it is thought that IRS-2 has a greater function in liver and islet ǃ cells (Sun, Wang et al. 1995). 
Once phosphorylated by IR, IRS-1 activates a cellular cascade and binds to p85 regulatory 
subunit of phosphatidylinositol (PI) 3-kinase, which in turn activates the p110 catalytic 
subunit (Czech and Corvera 1999). To date, five isoforms of regulatory subunits of PI 3-
kinase have been identified in skeletal muscle, including two classical isoforms (p85ǂ and 
p85ǃ) and three other isoforms (p55ǂ, p55Ǆ, and p50ǂ) (Shepherd, Nave et al. 1997). 
Activated PI 3-kinase specifically phosphorylates the D3 position of the cellular 
phosphoinositides to produce phosphatidylinositol 3-monophosphate (PI-3-P), PI-3,4-
bisphosphate (PIP2), and PI-3,4,5-triphosphate (PIP3) (Alessi, Deak et al. 1997; Alessi 2001). 
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These unique phospholipids serve as docking sites for cytoplasmic proteins with pleckstrin 
homology (PH) domains, including the serine/threonine kinases Akt/PKB and 
phosphoinositide-dependent kinase-1 (PDK1). The PH domain of Akt/PKB is displaced by 
3-phosphoinositides and exposes regulatory phosphorylation sites in the 
catalytic/regulatory domain of the enzyme. Moreover, by recruiting both Akt and PDK1 to 
common membrane domains, the two enzymes come into closer proximity, promoting the 
phosphorylation of the Thr308 residue by PDK1. Ser473 phosphorylation is promoted by 3-
phosphoinositides, through a second mechanism not involving the recruitment of Akt to the 
plasma membrane, which is required for Thr308 phosphorylation. The enzyme responsible 
for phosphorylating Ser473 site has not yet been cloned (Hresko, Murata et al. 2003; Murata, 
Hresko et al. 2003). To date, glucose transporter 4 (GLUT 4) translocation stimulated by 
Akt/PKB from intracellular compartments to the cell surface membrane in response to 
insulin in skeletal muscle and adipose tissue is not fully understood.  
3.2 T1DM: to be or not to be insulin resistant, that is the question 
As described previously, T1DM is characterized by hyperglycaemia, i.e., glucose toxicity, 
which leads to insulin resistance in T1DM patients (Patti, Maffettone et al. 1999). Since 
T1DM severity is correlated with the degradation of pancreatic ǃ-cell, most T1DM patients 
are believed to have varying degree of insulin resistance. A series of studies have 
demonstrated 30-50% decreases in rates of insulin-stimulated glucose transport in T1DM 
patients (DeFronzo 1982; DeFronzo, Hendler et al. 1982; Yki-Jarvinen, Kiviluoto et al. 1986; 
Vuorinen-Markkola, Koivisto et al. 1992; Chillaron, Goday et al. 2009). One of potential 
trigger for disturbance of glucose uptake in T1DM results from elevated intramyocellular fat 
in human skeletal muscle (Krssak, Falk Petersen et al. 1999). In addition, it is well 
established that T1DM incidence may be related to overweight and obesity especially in 
children (Baum, Ounsted et al. 1975). More recently, several studies have demonstrated that 
obesity in childhood was highly related to the risk of subsequent T1DM (Kordonouri and 
Hartmann 2005; Ljungkrantz, Ludvigsson et al. 2008; Lammi, Moltchanova et al. 2009). Two 
factors are principally known to be the main components of the relationship between 
obesity and diabetes: insulin resistance and insulin deficiency (Felber and Golay 2002). 
These two factors are closely associated in a dual regulatory cycle in which high blood 
glucose levels promote insulin production which, in turn, reduces the increase in glycemia 
(Ferrannini and Camastra 1998). The effect of glucose is elicited by generating, stimulating, 
and amplifying signals in the ǃ-cells (Henquin 2000). Chronic high levels of blood glucose 
create a glucotoxic milieu, impairing insulin sensitivity. Hence, genetic basis in the 
development of diabetes for people suffering from obesity could explain both insulin 
resistance and insulin deficiency (Gerich 1998). As peripheral insulin resistance increases, 
the adipose tissue produces more fatty acids, and in turn, impaired liver production of 
glucose. Thus, pancreatic ǃ-cells may fail to maintain insulin homeostasis (Hegarty, Furler et 
al. 2003). Chronic hyperglycemia is an independent cause of insulin resistance with clinical 
importance in the treatment of T1DM (Vuorinen-Markkola, Koivisto et al. 1992). Obesity 
induces an elevation of delivery of fatty acids in the blood stream that can promote an 
accumulation of long chain fatty acyl-CoA (LCFACoA), diacylglycerol, and ceramides. 
These metabolically active molecules stimulate a serine/threonine kinase cascade leading to 
phosphorylation of serine/threonine sites on IRS-1 and IRS-2, which in turn decreases the 
capability of the IRSs to activate PI3 kinase (Dresner, Laurent et al. 1999; Itani, Ruderman et 
al. 2002). A more recent study indicated that intracellular LCFACoA is associated with an 
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increased activation of PKCθ and a decrease in both IRS-1 tyrosine phosphorylation and 
IRS-1 associated PI3 kinase activity, which is involved in an increased IRS-1 Ser307 
phosphorylation. Insulin signaling cascade is eventually altered, thereby impairing glucose 
uptake (Dresner, Laurent et al. 1999; Patti, Maffettone et al. 1999; Itani, Ruderman et al. 
2002). In addition, a study from Thompson and Cooney (Thompson, Lim-Fraser et al. 2000) 
indicated that LCFACoAs decreased hexokinase activity in homogenates of human and rat 
soleus muscle in vitro. Hexokinase is the first enzyme of intracellular glucose metabolism 
and its suppression by LCFACoA might well account for a decrease in glucose influx into 
the muscle tissue. Furthermore, defects in Akt phosphorylation may also be associated with 
decreased glucose uptake in T1DM. A study demonstrated that Akt phosphoryation was 
significantly impaired in insulin-resistant hypoglycemic Goto-Kakizaki rats and this 
condition was normalized by a drug treatment, suggesting that Akt is a potential site of 
insulin resistance in T1DM patients (Krook, Kawano et al. 1997).  
4. The consequences of T1DM on protein metabolism 
T1DM patients exhibit overall changes in tissue protein metabolism. These changes are 
primarily the result of systemic hypoinsulinemia, changes in circulating hormones, 
intracellular signals, and catabolic factors also. T1DM-associated milieu disrupts tissue 
protein homeostasis and induces a net negative protein balance, particularly in skeletal 
muscle. Patients with T1DM often display profound skeletal muscle atrophy, which results 
in muscle weakness, fatigue, delayed recovery after illness, and has been linked with 
increased morbidity and mortality (Gordon, Serino et al.; Tisdale; Menconi, Fareed et al. 
2007). Skeletal muscle atrophy associated with T1DM results from the upregulation of 
numerous catabolic factors, which increase protein degradation and decrease processes of 
protein synthesis. Therefore, understanding the mechanisms underlying T1DM-mediated 
skeletal muscle atrophy is important for developing potential strategies to preserve or 
reverse losses in protein, maintain skeletal muscle function and improve the quality of life of 
people suffering from T1DM. The protein content of a tissue is the result of protein synthesis 
and degradation (Nair 1995). Numerous pathological diseases disrupt the balance between 
protein synthesis and degradation resulting in tissue wasting conditions. Although the 
specific mechanisms underlying the cause of wasting are not completely understood, these 
conditions display decreased stimulation of protein synthesis and increased expression of 
catabolic factors that enhanced catabolic activity. T1DM milieu induces protein wasting 
where skeletal muscle tissue is rapidly degraded in order to provide amino acid substrates 
for gluconeogenesis in the liver. 
4.1 Protein metabolism in the absence of insulin 
Whole body protein metabolism is typically measured using an isotopically labeled amino 
acid tracer such as L-[113C] or [114C] leucine. Leucine is an essential amino acid whose 
appearance, disappearance, transamination to its ketoacid (-ketoisocaproate or KIC), and 
oxidation can be measured to provide an indication of protein breakdown, synthesis, and 
metabolism (Charlton and Nair 1998). It has been demonstrated that whole-body leucine 
kinetics in T1DM patients indicated high levels of protein breakdown and metabolism with 
insulin deprivation relative to non-diabetic controls (Nair, Ford et al. 1995). These measures 
of protein breakdown, leucine transamination and oxidation are drastically decreased with 
insulin treatment indicating a decrease in catabolism and amino acid metabolism. 
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Interestingly, measures of whole body protein synthesis according to non-oxidative leucine 
flux were elevated in insulin-deprived T1DM patients above non-diabetic controls. When 
these patients were treated with insulin, a decrease in whole-body protein synthesis was 
observed (Nair, Ford et al. 1995; Charlton and Nair 1998). However, insulin treatment to 
fasted individuals without an increase in plasma amino acids caused a reduction in plasma 
amino acids (Charlton and Nair 1998). Several studies showed that when insulin treatment 
was administered to T1DM patients or healthy controls with an amino acid load increase in 
whole body protein synthesis occurred (Castellino, Luzi et al. 1987; Tessari, Inchiostro et al. 
1987; Luzi, Castellino et al. 1990; Inchiostro, Biolo et al. 1992), although other studies were 
unable to measure an increase in protein synthesis (Flakoll, Kulaylat et al. 1989; Bennet, 
Connacher et al. 1991). In order to understand the underlying mechanisms of whole body 
protein metabolism with insulin treatment, it appears useful to evaluate the relative changes 
in individual tissues and cellular compartments. The primary responsive tissues to insulin-
mediated changes in protein metabolism include hepatic, gastrointestinal, cardiac, and 
skeletal muscle. Numerous studies have measured the rates of protein synthesis and 
degradation using amino acid tracers (Charlton and Nair 1998). An increase in both protein 
degradation and protein synthesis has been observed in T1DM patients in the absence of 
insulin treatment (Charlton and Nair 1998; Herbert and Nair 2010). The rate of protein 
degradation in the absence of insulin treatment is higher than the rate of protein synthesis 
resulting in a net loss of whole body protein. T1DM patients in an insulin-deprived state 
display elevated skeletal muscle proteolysis and splanchnic bed protein synthesis. High 
rates of protein synthesis measured in the splanchnic bed may be related primarily to 
hepatic and/or gastrointestinal tissue activity. With insulin treatment, skeletal muscle 
proteolysis is inhibited while splanchnic bed protein synthesis is decreased. This decrease in 
splanchnic bed protein synthesis may be mediated by decreases in glucagon and 
gluconeogenic activity in hepatic tissue in response to insulin treatment (Herbert and Nair 
2010). The splanchnic bed has a much higher rate of protein turnover than skeletal muscle 
which could account for the association between splanchnic bed and whole-body protein 
metabolism (Charlton and Nair 1998). Therefore, despite the larger total mass of skeletal 
muscle relative to total splanchnic mass, whole-body protein metabolism is likely to mimic 
that of the rapid protein turnover splanchnic bed in T1DM patients.  
4.2 Lack of insulin in T1DM induces protein degradation  
Insulin is considered a potent anabolic hormone. Insulin treatment promotes skeletal muscle 
protein accretion primarily through inhibition of mechanisms of protein degradation 
(Charlton, Balagopal et al. 1997; Fawcett, Permana et al. 2007). Although studies do not 
agree whether insulin alone stimulates protein synthesis in vivo, insulin treatment plays an 
important role in supporting mechanisms of protein synthesis. Evidence supports a 
necessity for the presence of insulin and amino acids, (leucine in particular) in order to 
maximally stimulate skeletal muscle protein synthesis with feeding (Anthony, Yoshizawa et 
al. 2000; Balage, Sinaud et al. 2001; Anthony, Lang et al. 2002; Anthony, Reiter et al. 2002). 
Insulin receptor binding signals through the PI3K/AKT/mTORC1 pathway and mediates 
control of the mRNA binding step of translation initiation (Kimball and Jefferson; Anthony, 
Lang et al. 2002). The mammalian target of rapamycin complex 1 (mTORC1) is a prominent 
signaling protein where multiple positive and negative signals converge to influence the 
phosphorylation of downstream regulators of translation initiation, p70 S6K1 and eIF4E- 
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binding protein 4E-BP1 (Kimball and Jefferson). mTORC1 mediates phosphorylation and 
activation of protein kinase S6K1 which activates translation initiation and elongation 
factors leading to the activation of mRNA cap binding and mRNA joining to the 43 S 
preinitiation complex of the ribosome (Fenton and Gout; Kimball and Jefferson). In addition, 
mTORC1 mediated phosphorylation of 4E-BP1 decreases its affinity for binding translation 
initiation factor eIF4E, allowing it to interact with eIF4G in formation of the active mRNA 
cap-binding complex, eIF4F (Kimball and Jefferson; Anthony, Lang et al. 2002). Modulation 
of these two regulatory steps in translation initiation account for much of the increase in 
skeletal muscle protein synthesis with feeding in healthy non-diabetics (Kimball and 
Jefferson). Numerous animal studies have used chemical (streptozotocin, alloxan, diazoxide, 
and somatostatin) or procedures (pancreatecomy) to induce T1DM by abrogating the release 
of insulin from pancreatic -cells. These agents allow for the study of insulin’s influence on 
many physiological processes including protein metabolism. Using STZ-treated rats, we 
demonstrated a decrease in skeletal muscle mass (Kelleher). Skeletal muscle and liver 
protein synthesis are stimulated with increases in plasma amino acids and insulin 
(Yoshizawa, Kimball et al. 1998). The amino acid, leucine, is unique in its ability to stimulate 
skeletal muscle protein synthesis through the mTORC1 pathway (Anthony, Yoshizawa et al. 
2000). Carbohydrate feeding without the supplementation of amino acids increases serum 
insulin, but does not increase skeletal muscle protein synthesis (Anthony, Anthony et al. 
2000). Taken together, both amino acids (leucine) and insulin are required to stimulate 
muscle protein synthesis with feeding. In T1DM animal models, basal skeletal muscle 
protein synthesis is decreased relative to non-alloxan-treated controls, but increases 
proportionally with leucine gavage (Anthony, Reiter et al. 2002). Phosphorylation of 4E-BP1 
and S6K1 were either attenuated or unresponsive to leucine or meal feeding in the absence 
of insulin, but responded to leucine gavage in a dose-dependent manner to insulin 
treatment (Gordon, Serino et al.; Balage, Sinaud et al. 2001; Anthony, Lang et al. 2002; 
Anthony, Reiter et al. 2002). When insulin-unresponsive neonatal pigs were treated with 
leucine, increases in skeletal muscle protein synthesis were associated with increased eIF4E 
availability for eIF4F formation (Escobar, Frank et al. 2005). Therefore, feeding-induced 
skeletal muscle protein synthesis appeared to be both insulin-dependent (phosphorylation 
of 4E-BP1 and S6K1) and insulin-independent (eIF4E availability) mechanisms (Anthony, 
Reiter et al. 2002). Thus, decreases in the rate of skeletal muscle protein synthesis in T1DM 
can be attributed to multiple factors. Hypoinsulinemia has been shown to decrease feeding-
induced protein synthesis due to resistance to leucine stimulation of the translational 
regulators 4E-BP1 and S6K1 (Gordon, Serino et al.). Furthermore, the lack of circulating 
insulin reduces PI3K/AKT/mTORC1 pathway activation, a pathway which activates a 
multitude of anabolic signals and inhibits catabolic factors when stimulated (Price, Bailey et 
al. 1996). In T1DM the inflammatory and hormonal milieu increase protein degradation and 
decrease synthesis.  
4.3 O-GlcNAcylation of proteins 
Interestingly, hyperglycemia induced by the lack of insulin in T1DM is also capable of 
interfering with mechanisms of protein synthesis. Glucose can be converted to uridine 
diphosphate N-acetylglucosamine (UDP-GlcNAc) through the cellular energy sensor 
hexosamine biosynthetic pathway (Love and Hanover 2005). Hyperglycemia with less well-
controlled diabetes can increase the amount of O-linked ǃ--N-acetylglucosamine (O-
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GlcNAc) (Park, Saudek et al.). Increased site-specific O-GlcNAcylation of proteins can be 
detrimental to protein function thus potentially contributing to the deleterious effects of 
hyperglycemia seen in T1DM on liver, -cell, pancreatic, and red blood cell function (Issad, 
Masson et al.; Park, Saudek et al.). O-GlcNAcylation of proteins is involved with 
transcription, translation, ubiquitination, cell cycle, stress responses, and similar to 
phosphorylation can alter protein posttranslational function and cycle proteins on and off 
(Butkinaree, Park et al.; Love and Hanover 2005). In T1DM, there is a loss of regulation of O-
GlcNAcylation and a crosstalk with protein phosphorylation can potentially underlying 
many of the abnormal protein functions and glucotoxicity exhibited by the disease. O-
GlcNAcylation may compete with phosphorylation at key sites in the insulin signaling 
pathway (Love and Hanover 2005). High throughput studies have identified O-
GlcNAcylation sites on translation factors and core ribosomal proteins that form active 
polysomes (Zeidan, Wang et al.). Thus modification of ribosomal proteins and signaling 
pathways by O-GlcNAcylation may play a role in T1DM-associated regulation of signal 
transduction and translation. 
5. Hormonal influences on T1DM protein metabolism 
The lack of circulating insulin resulting from ǃ-cell destruction disrupts the production and 
release of other hormones. T1DM patients and animal models display increases in glucagon, 
glucocorticoids, catecholamines, and growth hormone which may influence changes in 
tissue specific protein metabolism independent of hypoinsulinemia. These hormones are the 
most prominent hormones affecting changes in protein metabolism when hypoinsulinemia 
results in their irregular production and release. 
5.1 Glucagon 
Basal energy expenditure was increased in T1DM following insulin withdrawal when 
compared to insulin treatment and non-diabetic control subjects (Nair, Halliday et al. 1984; 
Charlton and Nair 1998; Karakelides, Asmann et al. 2007). Insulin deprivation in T1DM 
patients displayed elevations in plasma glucagon which correlate with increased energy 
expenditure (Nair, Halliday et al. 1984). Evidence support that increased circulating 
glucagon the ability to increase leucine and phenylalanine oxidation, proteolysis, and 
whole-body oxygen consumption in T1DM (Nair 1987; Nair, Halliday et al. 1987; Charlton 
and Nair 1998). In addition to stimulating proteolysis, glucagon induced inhibition of 
muscle protein synthesis by reducing glucogenic plasma amino acids (Charlton, Adey et al. 
1996). High circulating glucagon levels are likely to increase oxygen consumption by 
stimulating the energy-expensive process of gluconeogenesis, and macroautophagy in the 
liver of T1DM patients (Nair, Halliday et al. 1984; Mortimore, Poso et al. 1989; Chhibber, 
Soriano et al. 2000; Karakelides, Asmann et al. 2007). Enhanced hepatic glucose production 
along with increases in splanchnic region protein synthesis could be attributed to the 
increases in basal energy expenditure measured in insulin-deprived T1DM (Herbert and 
Nair 2010). 
5.2 Catecholamines 
Animal models of T1DM display increases in norepinephrine and IL-1-mediated 
epinephrine (Gwosdow, O'Connell et al. 1992; Baviera, Zanon et al. 2008). IL-1, a key 
mediator of inflammation, fever, and acute phase response plays an important role in the 
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incidence of T1DM (Mandrup-Poulsen, Pickersgill et al.). IL-1 has been shown to stimulate 
catecholamine release and mediate a stimulatory effect on corticosterone release from the 
adrenal gland through an -adrenergic receptor (Gwosdow, O'Connell et al. 1992). 
Catecholamines have been shown to inhibit muscle protein degradation via a cyclic 
adenosine monophosphate (cAMP) signaling cascade (Baviera, Zanon et al. 2007). 
Guanthidine-induced chemical sympathectomy of STZ-induced diabetes rats indicates that 
catecholamines inhibit protein degradation through both Ca2+-dependent and ATP-
dependent pathways (Baviera, Zanon et al. 2008) that could provide prophylaxis in 
understanding the disruption of proteins homeostasis in T1DM. 
5.3 Glucocorticoids  
Catabolic doses of glucocorticoids have been implicated in a number of muscle wasting 
diseases including T1DM where increases in corticosterone production have been observed 
(Bailey, Wang et al. 1999; Menconi, Fareed et al. 2007). Circulating increases in TNF- and 
IL-1 can stimulate the pituitary-adrenal axis to increase secretion of corticosterone 
(Gwosdow, Kumar et al. 1990; Hall-Angeras, Angeras et al. 1990). Insulinopenia, together 
with increased glucocorticoids have been shown to enhance muscle protein degradation 
through increased ubiquitin conjugation to proteins, proteolytic activity, and ubiquitin 
pathway component mRNA transcription (Price, Bailey et al. 1996; Bailey, Wang et al. 1999). 
Elevated levels of glucocorticoids have also been found to contribute to skeletal muscle 
atrophy through increased expression of ubiquitin pathway proteins, transcription factors 
CCAAT/enhancer-binding protein  and  and Forkhead box O (Foxo), and nuclear cofactor 
p300/histone acetyl transferase (Menconi, Fareed et al. 2007). In addition to catabolic factors, 
glucocorticoids contribute to muscle atrophy through inhibition of anabolic factors, insulin 
signaling, and stimulation of protein synthesis (Shah, Kimball et al. 2000; Shah, Kimball et 
al. 2000; Hu, Wang et al. 2009). Glucocorticoids induce insulin and insulin-like growth factor 
(IGF-1) resistance through inhibition of the phosphoinositide-3-kinase(PI3K)/protein kinase 
B(AKT) pathway. This mechanism is believed to be caused by interference with PI3K-p85 
subunit interaction, preventing activation of insulin receptor substrate-1 (IRS-1) and 
autoinhibition of the ribosomal protein S6 kinase (p70 S6K1) enzyme (Zheng, Ohkawa et al.; 
Shah, Iniguez-Lluhi et al. 2002; Hu, Wang et al. 2009). Increases in circulating 
glucocorticoids also contribute to the observed decreases in the rate of protein synthesis. In 
addition to their effects on protein degradation, glucocorticoids inhibit muscle protein 
synthesis through insulin, IGF-1, and leucine resistance. Despite no changes in heart, type I 
fiber, or liver protein synthesis with glucocorticoid administration for days, rates of skeletal 
type II muscle fiber protein synthesis were inhibited and maintained at a lower rate 
(Rannels and Jefferson 1980; Odedra, Bates et al. 1983). Inhibition of skeletal muscle protein 
synthesis is partially protected by increases in insulin administration in STZ-induced 
diabetic rats, but cannot produce positive accretion rates with increasing doses (Tomas, 
Murray et al. 1984) and even low doses of corticosterone induce muscle wasting with low 
doses of insulin administration in STZ-treated rats (Odedra and Millward 1982). 
Glucocorticoids appear to inhibit muscle protein synthesis through dephosphorylation and 
inhibition of 4E-BP1 and S6K and enhanced phosphorylation of eIF4E (Shah, Kimball et al. 
2000; Shah, Kimball et al. 2000) along with mechanisms of anabolic factor resistance (Rieu, 
Sornet et al. 2004). 
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5.4 Growth hormone  
Growth hormone inhibits leucine oxidation and stimulates skeletal muscle protein synthesis, 
but does not appear to affect mechanisms of protein degradation (Horber and Haymond 
1990). Basal growth hormone levels in T1DM patients are normal or elevated when 
compared to non-diabetics controls depending on glycemic control. Interestingly, IGF-1 
levels have been shown to be reduced in T1DM patients (de Sa, Nascif et al.). Alterations to 
the growth hormone-IGF-1 axis have been linked to hepatic resistance caused by reduced 
receptors expression and circulating growth hormone binding protein (Bereket, Lang et al. 
1999). Poor metabolic control in T1DM alters the growth hormone/IGF-1 axis, but 
administration of insulin or insulin plus IGF-1 maintain the metabolism associated with this 
axis. T1DM-mediated hyperglycemia has not been shown to interfere with the rest of the 
hypothalamic-pituitary axis according to GH-, ACTH and cortisol-releasing mechanisms (de 
Sa, Nascif et al.; Moyer-Mileur, Slater et al. 2008). 
6. Protein degradation, proteolysis, and pro-catabolic potential signals 
involved in T1DM 
Tissue mass is the product of both anabolic and catabolic processes. In order to evaluate the 
fluctuation in tissue size, both rates of protein synthesis and protein degradation are 
important in order to understand the net protein flux. Protein degradation is important to 
control the rate-limiting and regulatory proteins in signaling pathways, remove mutated or 
damaged proteins, and to supply amino acids from muscle proteins for protein synthesis 
and gluconeogenesis (Price and Mitch 1998). There are four intracellular pathways utilized 
by eukaryotic cells to degrade proteins including the ATP-dependent ubiquitin-proteasome 
system, calcium-dependent protease, the lysosomal acid-activated protease, and the ATP-
independent caspase pathways. T1DM is a pathological disease with considerable increases 
in protein degradation.  
6.1 ATP and calcium-dependent proteolytic processes 
Virtually all muscle wasting conditions such as T1DM exhibit increases in protein 
degradation through activation of the ubiquitin-proteasome system (Hu, Lee et al. 2007). 
Proteins are degraded in this ATP-dependent proteolytic process when conjugated by 
covalent attachment to an ubiquitin protein. With the aid of ATP hydrolysis, ubiquitin is 
transferred between several enzymes (E1, E2, and E3) prior to attachment at specific lysine 
residues on the target protein serving as a marker for proteolytic degradation. This process 
is repeated until several ubiquitin proteins are attached in a linear chain targeting the 
protein for degradation in the proteasome 26S. When targeted proteins meet the 
proteasome, they are unfolded and fed into the proteasome core where combinations of 
peptide sequence are recognized and hydrolyzed (Price and Mitch 1998). Calcium-
dependent protein degradation has been shown to depend on the activity of a family of 
cysteine proteases called calpains (Costelli, Reffo et al. 2005). Calpains typically exist as 
inactive heterodimers in the cytoplasm. When the intracellular calcium concentration rises, 
calpains translocate to the plasma membrane where they are activated by phospholipids 
which induces a conformational change. This structural change removes regulatory 
constraints from the catalytic domain, and the catalytic subunit is released in an active state. 
Thus calpains might be involved in T1DM-related muscle wasting through their mechanism 
of myofibrillar degradation. Calpains attack the sarcomeric proteins of the Z-disk which 
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leads to a disruption of the myofibrils and release of protein substrates for degradation by 
other proteolytic systems (Costelli, Reffo et al. 2005). 
6.2 Ubiquitin-proteasome involvement in T1DM-induced muscle wasting 
Two muscle protein degradation systems that operate independent of both ATP and calcium 
include the recruitment of caspases and the endosome-lysosome system and may be 
upregulated in T1DM. ATP-independent processes of protein degradation involve caspases, 
cysteine proteases commonly activated with the apoptotic response. A reduction in myonuclei 
associated with increases in apoptosis indicate that apoptosis plays a role in some models of 
muscle wasting. However, caspase-3 activation also can mediate skeletal muscle atrophy 
through actomyosin complex cleavage. Evidence suggests that caspase-3 activation is an initial 
step in the process of muscle protein degradation which cleaves larger actomyosin complexes 
into smaller fragments for other systems (ubiquitin-proteasome) to degrade (Du, Wang et al. 
2004). The lysosomal acid-activated protease or endosome-lysosome system primarily 
degrades long-lived proteins using activated acid proteases in non-selective manner (Costelli, 
Reffo et al. 2005). This system is commonly incorporated in the recycling of substrates with 
autophagy. Although some of these proteases are abundant, lysomal degradation is not often 
involved in skeletal muscle wasting. Protein degradation studies on STZ-induced diabetes 
indicated increases in the ubiquitin-proteasome and calpain pathways that could be 
responsible for the skeletal muscle wasting observed with uncontrolled T1DM (Kettelhut, 
Pepato et al. 1994; Pepato, Migliorini et al. 1996). These studies measured the activity of these 
pathways in addition to the endosome-lysosomal system for 10 days post-STZ injection and 
observed variable changes in the systems over time. Within the first 3 days, the increase in 
skeletal muscle proteolysis was associated with activation of the ubiquitin-proteasome and 
calpain pathways, and increases in ubiquitin and proteasome subunit mRNA. At 5-10 days 
post-injection, the activity of these pathways decreased below non-diabetic control measures. 
The endosome-lysosomal system did not appear to be activated throughout the 10 days of 
diabetes, and caspase activity could not be measured at this point. After 24 hours of diabetes, 
rates of protein synthesis were reduced and continued to decrease for the remaining 10 days. 
Therefore, the STZ-treated animal model appears to develop muscle atrophy as a result of 
increased ubiquitin-proteasome and calpain pathway activation in addition to decreases in the 
rate of protein synthesis. In agreement with these two STZ-treatment studies above, increases 
in skeletal muscle protein degradation in patients and other animal models of T1DM is 
primarily associated with activation of the ubiquitin-proteasome system (Flakoll, Kulaylat et 
al. 1989; Smith, Wong et al. 1989; Price, Bailey et al. 1996). Uncontrolled STZ-induced diabetes 
in rats exhibits increases in both proteolytic capacity and activity (Kettelhut, Pepato et al. 1994; 
Pepato, Migliorini et al. 1996; Price, Bailey et al. 1996; Hu, Lee et al. 2007; Hu, Klein et al. 2008). 
In STZ-treated rats, the use of lysosomal and calcium-dependent degradation pathways 
inhibitors was unable to prevent skeletal muscle proteolysis (Price, Bailey et al. 1996). 
However, inhibition of the proteasome (MG132) or ATP synthesis decreased muscle 
proteolysis to similar levels compared to vehicle-treated controls. Therefore the ATP-
dependent ubiquitin-proteasome pathway seems to mediate protein degradation in T1DM 
(Price, Bailey et al. 1996; Bailey, Wang et al. 1999).  
6.2.1 Atrophy in T1DM 
Additional evidence of the role of the ubiquitin-proteasome pathway in T1DM is the 
increased transcription of muscle atrophy-related genes in insulinopenic STZ-treated rats 
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(Price, Bailey et al. 1996). Muscle specific ubiquitin E3 ligases atrogin-1/MAFbx, muscle 
RING finger protein 1 (MuRF1), ubiquitin-conjugating enzyme E2 (14 kDa), and the C3, C5, 
and C9 proteasome subunits are important ‘atrogenes’ in the regulation of muscle mass and 
typically measured as indicators of muscle proteolytic capacity (Zheng, Ohkawa et al.; Wing 
and Bedard 1996; Bailey, Wang et al. 1999; Menconi, Fareed et al. 2007). Atrogene mRNAs 
are typically increased with insulin deficiency or resistance in conditions of muscle wasting 
and decreased or degraded with insulin and IGF-1 signaling (Wing and Bedard 1996; Price 
and Mitch 1998). Atrogin-1 and MuRF1 mRNA levels are common indicators of myofibrillar 
degradation because atrogin-1 targets eukaryotic initiation factor 3 subunit 5 that induces 
expression of muscle specific proteins and hypertrophy, and MuRF1 targets myosin in 
muscle (Tisdale). These gene products are atrophy-specific ubiquitin ligases transcribed 
with FOXO3a activation and nuclear translocation. Increases in atrogin-1 and MuRF1 
transcription could indicate that the cell in T1DM is preparing for increases in muscle 
protein-specific proteolysis. In addition, transcription of atrogenes, expression levels of 26S 
proteasome and ubiquitin are measured as indicators of proteolytic capacity. Ubiquitin 
conjugation to proteins provides a way of analyzing which proteins are marked for 
proteolytic degradation. Finally, the chymotrypsin-like peptidase activity of homogenized 
tissue in the presence and absence of epoxomicin, a proteasome-specific inhibitor, provides 
a measure of ubiquitin-proteasome activity (Hu, Klein et al. 2008). According to such 
measurements, skeletal muscle tissue taken from uncontrolled T1DM patients and animal 
models, strongly indicate activation of the ubiquitin-proteasome system as the primary 
mode of protein degradation in T1DM. Insulin regulates proteolysis through multiple 
signals, but direct regulates proteolytic activity through a zinc metalloproteinase, insulin-
degrading enzyme (IDE) (Duckworth, Bennett et al. 1998; de Tullio, Morelli et al. 2008). IDE 
co-purifies with the proteasome as part of a cytosolic complex (Duckworth, Bennett et al. 
1994). If IDE-proteasome interaction is prevented or IDE activity inhibited, insulin’s 
inhibitory effect on proteolytic activity is not observed (Bennett, Hamel et al. 1997; 
Duckworth, Bennett et al. 1998; Hamel, Bennett et al. 1998). Although insulin is the primary 
substrate for IDE, atrial natriuretic peptide, glucagon, proinsulin, IGF-1 and IGF-2 can also 
bind, get degraded by IDE, and have inhibitory effects on the chymotrypsin-like and 
trypsin-like catalytic activities of the proteasome (Bennett, Hamel et al. 1997). However, not 
all substrates equally inhibited proteolytic activity. Insulin analogues with various 
susceptibility to degradation by IDE showed a positive correlation between substrate 
degradation, proteolytic activity, and IDE-proteasome dissociation (Bennett, Fawcett et al. 
2003). The mechanism by which insulin causes intracellular inhibition of proteolytic activity 
may be through fragments of degraded insulin or conformational changes in the IDE-
proteasome complex (Bennett, Hamel et al. 1997; Hamel, Bennett et al. 1998; Bennett, 
Fawcett et al. 2003). Thus, increases in skeletal muscle proteolytic activity in uncontrolled 
T1DM are likely associated with a lack of IDE-mediated proteasome inhibition. 
6.2.2 Cross-talk between anabolic-catabolic signaling 
Extensive crosstalk between cellular signaling pathways regulates the processes of protein 
synthesis and degradation. Insulin, IGF-1, and leucine are among anabolic factors which 
signal through the PI3K/AKT/mTORC1 pathway, activating regulatory proteins associated 
with translation initiation and inhibiting mechanisms of protein degradation. 
Glucocorticoids and circulating proinflammatory cytokines are among catabolic factors 
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which signal in opposition to insulin by inhibiting mechanisms of protein synthesis and 
increasing ubiquitin-proteasome pathway activity and apoptosis (Tisdale; Menconi, Fareed 
et al. 2007). A benefit of crosstalk between the protein synthetic and degradation pathways 
is that it can prevent energy expensive futile cycles. However, crosstalk can also create 
resistance to anabolic signals in conditions of muscle wasting (Rieu, Sornet et al. 2004). A 
strong reciprocal relationship exists between PI3K/AKT pathway activation and protein 
degradation in T1DM. Decreases in PTEN, the phosphatase which turns off PI3K signaling 
by inactivating phosphatidylinositol 3,4,5-triphosphate (PIP3) to phosphatidylinositol 4,5-
bisphosphate (PIP2), was shown to suppress STZ-induced increases in proteolysis by 
maintaining PI3K signaling (Hu, Lee et al. 2007). PI3K/AKT pathway activation can be 
decreased in T1DM due to hypoinsulinemia in addition to an increase in circulating 
glucocorticoids. Glucocorticoids have been found to decrease IRS-1-mediated PI3K signaling 
due to increases in PI3K-glucocortioid receptor interaction (Hu, Wang et al. 2009). 
Glucocorticoid receptor stimulation contributes to muscle protein degradation through 
inhibition of insulin signaling and can activate muscle proteolysis independently of insulin 
signaling pathways. The lack of PI3K/AKT activation observed in T1DM models is coupled 
with increases in both ubiquitin-proteasome activity, and ATP-independent proteolysis in 
the activation of caspase-3 in skeletal and cardiac muscle (Hu, Lee et al. 2007; Hu, Klein et al. 
2008). When the PI3K/AKT pathway is not activated, protein degradation pathways are 
activated through the dephosphorylation and activation of Foxo’s (Sandri, Sandri et al. 2004; 
Baviera, Zanon et al. 2008). FOXO3a, a critical mediator between growth factor IRS-
1/PI3K/AKT and IRS2/MEK/ERK signaling, induces the expression of ubiquitin, atrogin-1, 
and MuRF1 (Tisdale; Zheng, Ohkawa et al.; Sandri, Sandri et al. 2004). In addition to 
atrogenes, FOXO3a is responsible for apoptotic signaling leading to the loss of 
mitochondrial membrane permeability, degradation of nuclear DNA, cytochrome c release, 
Bad phosphorylation, downregulation of FLICE-inhibitory protein, and cleaved (active) 
caspase 1, 3, and 8 (Hou, Chong et al.; Shang, Chong et al.; Skurk, Maatz et al. 2004). 
Therefore, FOXO3a may represent a promising target for the treatment of T1DM-mediated 
skeletal muscle atrophy. 
6.3 Inflammation and increases in protein degradation in T1DM 
As discussed previously in this chapter, pro-inflammatory cytokine play a key role in the 
pathogenesis of T1DM. Increases in plasma cytokines can have detrimental effects on 
multiple tissues and is associated with skeletal muscle wasting. For example, aged rats with 
low grade inflammation resulted in an insensitivity to feeding-induced skeletal muscle 
protein synthesis (Balage, Averous et al.). Furthermore, inflammation is implicated in the 
increases in muscle protein degradation, reductions in muscle protein synthesis, and 
reduced intake of amino acids in a number of pathological conditions (Durham, Dillon et al. 
2009). Circulating inflammatory cytokines can alter the release of hormones from the 
pituitary gland including inflammatory-suppressive glucocorticoids, or can have direct 
signaling effects on target tissues. The changes in protein metabolism associated with T1DM 
point towards TNF-ǂ, and IL-1 as pro-inflammatory cytokines which play a role in skeletal 
muscle atrophy. TNF-ǂ and IL-1 are capable of inducing both direct and indirect effects on 
skeletal muscle metabolism. TNF-ǂ can inhibit skeletal muscle protein synthesis by 
inhibiting phosphorylation of 4E-BP1 (Tisdale 2005). This cytokine is further implicated as a 
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mediator of skeletal muscle atrophy through the activation of NF-κB. NF-κB activation can 
inhibit synthesis of the muscle-specific differentiation factor MyoD and is posited to be the 
stimulator of ubiquitin-proteasome activity induced by cytokines, proteolytic-inducing 
factor (PIF), and reactive oxygen species (Libera and Vescovo 2004; Tisdale 2005; Durham, 
Dillon et al. 2009). However, it should be noted that these conclusions come from the 
literature associated with cancer cachexia and not T1DM, and increases in TNF-ǂ 
administration or expression do not always show direct catabolic signaling. In septic rats, 
TNF-ǂ increased myofibrillar breakdown rates with no changes in the rate of muscle protein 
synthesis (Zamir, Hasselgren et al. 1992). In healthy rats, TNF-ǂ and IL-1ǂ administration 
display increases in skeletal muscle proteolysis by different mechanisms (Zamir, Hasselgren 
et al. 1992). In these studies, TNF-ǂ administration only increased muscle proteolysis when 
the effects of glucocorticoids were not inhibited (Hall-Angeras, Angeras et al. 1990; Zamir, 
Hasselgren et al. 1992). With glucocorticoid inhibition (adrenalectomy or receptor 
antagonist), TNF-ǂ did not have any effect on protein turnover. IL-1ǂ, on the other hand 
increased muscle proteolysis independently of glucocorticoid inhibition (Zamir, Hasselgren 
et al. 1992; Zamir, Hasselgren et al. 1993). Therefore, it was determined from these studies 
that TNF-ǂ increased muscle proteolysis by stimulating the adrenal axis to increase release 
of glucocorticoids, while IL-1ǂ can stimulate glucocorticoid release and signal muscle 
proteolysis independently of the mechanism of glucocorticoids (Gwosdow, Kumar et al. 
1990; Hall-Angeras, Angeras et al. 1990). TNF-ǂ is an important pro-inflammatory cytokine 
for understanding T1DM-associated skeletal muscle wasting because it can activate also 
apoptotic signaling pathways. TNF-ǂ is capable of inducing production of a second 
messenger, sphingosine, which signals skeletal muscle cell apoptosis (Dalla Libera, 
Sabbadini et al. 2001). The interaction between TNF-ǂ and TNF receptor 1 has been shown 
to cause rapid degradation of sphingomyelin which generated sphingosine inside the cell 
(Wiegmann, Schutze et al. 1992). Although this observation is more common to models of 
heart failure than STZ-treatment, the number of apoptotic nuclei is positively correlated 
with circulating TNF-ǂ in T1DM, and the ensuing reduction in number of myonuclei may be 
responsible for skeletal muscle atrophy (Vescovo, Ambrosio et al. 2001). Therefore, wasting 
of skeletal muscle in T1DM may be linked to increases in pro-inflammatory regulators such 
as TNF-ǂ and IL-1 which can influence mechanisms of protein degradation and apoptosis. 
7. Conclusion  
The focus of this chapter was on the various cellular signaling-associated with inflammation 
that could explain either the etiology or pathogenesis of T1DM. Although the exact cause of 
T1DM is still unknown, we have gained insight into the cellular mechanisms that are 
involved. T1DM is defined as an autoimmune disease, therefore inflammatory-related 
signaling cascades are critical to understand to discover new therapeutic treatment. Among 
the several transcription factors, NF-B is of particular interest as it is involved in both the 
inflammatory and apoptosis process that could explain the degradation of -cells. T1DM 
milieu influences also mechanisms of protein synthesis and protein degradation. A focus 
was placed on changes in the skeletal muscle due to the important of muscle in glucose 
metabolism. As treatments improve, more research is needed to help combat the 
consequences of T1DM on the quality of life. 
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